Novo Nordisk News

Novo Nordisk's chief executive, Mike Doustdar, believes investors are underestimating the potential of the company's drugs, despite being a year into a corporat

Despite Wegovy making Novo Nordisk Europe's most valuable company, the Danish drugmaker faces challenges in finding its next blockbuster drug, with a recent pha

Novo Nordisk, the maker of Ozempic, saw its market value drop by $30 billion after a failed trial for a new experimental heart drug, drawing criticism from anal

Novo Nordisk is seeking a court injunction to block Eli Lilly's weight-loss drug advertisements, alleging that Lilly's ads mislead consumers with outdated studi

Two weight-loss drugmakers, Novo Nordisk and Eli Lilly, are engaged in a legal battle over the effectiveness of their respective medications.

Novo Nordisk has sued rival Eli Lilly in a U.S. federal court, alleging false advertising regarding the efficacy of Lilly's weight-loss medicines compared to No

Novo Nordisk has filed a lawsuit against Eli Lilly, accusing its GLP-1 rival of using outdated data in its advertising campaigns.

Novo Nordisk is suing Eli Lilly, alleging that its rival used "false and materially misleading" advertisements for its weight-loss and anti-diabetes treatments.

Novo Nordisk is suing Eli Lilly, alleging false advertising by using outdated clinical trial data to misrepresent the effectiveness of its drugs.

Novo Nordisk is suing Eli Lilly in U.S. federal court for alleged false advertising regarding its weight-loss drugs, seeking to block Lilly's ads and implement

Novo Nordisk has filed a lawsuit against Eli Lilly, alleging that its rival used outdated data in advertisements to falsely claim its weight-loss products were

India's drug regulator has approved Novo Nordisk's obesity drug Wegovy for the treatment of MASH, a severe form of fatty liver disease, following a committee re

Novo Nordisk India has launched Awiqli, the first once-weekly basal insulin for diabetes, aiming to reduce injections from daily to weekly for the over 101 mill

India has received the world's first once-a-week insulin, Awiqli, developed by Novo Nordisk.

Novo Nordisk has launched a new once-weekly insulin shot in India, priced at Rs 261 per week, aiming to help more diabetic patients switch to the new treatment.

India has received Novo Nordisk's Awiqli, a new once-weekly insulin injection for adults with diabetes, significantly reducing the frequency of basal insulin do

Novo Nordisk has launched its once-weekly insulin, Awiqli, in India at ₹261 per week, making India the seventh market for the drug. This initiative aims to addr

Novo Nordisk has launched Awiqli, a new weekly insulin shot, in India, priced at ₹261 for a 70-unit dose.

Novo Nordisk has launched Awiqli, a new once-weekly basal insulin injection, in India to provide an alternative to daily injections for diabetes patients and ad

Novo Nordisk has introduced Awiqli, a once-a-week insulin priced at Rs 2,600 per pen, significantly reducing the frequency of injections for patients.